Recently improved understanding of the pathogenesis of human head and neck squamous cell carcinoma (HNSCC) has led to the development of new, molecularbased therapeutic strategies, one of the more promising is the utilisation of tyrosine kinase (TK) inhibitors, targeting epidermal growth factor receptor (EGFR). In this study, we tested for gefitinib effectiveness in a broad panel of 12 newly established HNSCC cell lines, investigating its ability to reduce cell growth, to induce apoptosis and to modulate cell cycle and various EGFR pathway-related targets. Gefitinib IC 50 values ranged between 0.064 and 33 μM, its capability to induce apoptosis and cell accumulation in G0/G1 phase was cell line-specific, and the main EGFR-related pathway involved in gefitinib activity was PI3K/Akt/mTor. We characterised our in vitro panel extensively, with the aim to identify predictive factors for gefitinib effectiveness; all cell lines were free of human papillomavirus infection, two were positive for Fhit expression, four expressed wild-type p53, and all of them variously expressed the other two p53 family members, p63 and p73. The comparison between the targets analysed and gefitinib effectiveness evidenced the absence of a clear relationship, excluding them as predictive factors for gefitinib efficacy. Our results confirmed the in vitro efficacy of an anti-EGFR approach, but other targets than those analysed here should be characterised in order to identify valid predictive factors for gefitinib utilisation.
Introduction
Head and neck squamous cell carcinoma (HNSCC) is one of the most frequently occurring cancers worldwide, and the overall survival period is very short as the cancer often metastasises in the lymph nodes of the throat (1, 2) . The failure of conventional chemotherapy, which does not increase the overall survival rate of patients, and the goal of identifying new biological targets for anticancer therapy, has stimulated the study of the molecular mechanisms of HNSCC progression (3) (4) (5) . Among the promising new cellular targets, epidermal growth factor receptor (EGFR) seems to have a prominent role since it has been recognised as a prognostic factor in head and neck cancer (6, 7) . It was recently suggested that gefitinib (ZD1839; Iressa), an orally active, selective EGFR tyrosine kinase (TK) inhibitor (8) could be utilised in head and neck cancer therapy (9,10 and www.clinicaltrials.gov). This drug is a quinazoline derivative that selectively inhibits EGFR tyrosine kinase activity by binding the receptor at the ATP-site, and is in clinical use in lung cancer patients (11) . The utilisation of gefitinib in preclinical studies and early clinical trials has recently shown evidence of its promising activity in head and neck cancer treatment (9, 10, 12) . However, an important aspect that remains unclear in the utilisation of TK inhibitors relates to the difficulty of identifying any predictive factor that is applicable in all tumour types. It would therefore be of value to confirm the hypothesis that the efficacy of EGFR-targeting drugs in head and neck cancer is linked to EGFR tumour level, as recently suggested by Janmaat et al (13) . Other biomarkers that have been suggested as predictive factors for gefitinib efficacy in other cancers, are increased EGFR gene copy number beyond EGFR protein expression, the presence of specific EGFR mutations and constitutive Akt activation (14) (15) (16) (17) (18) (19) .
In relation to other tumour types, an extensive pre-clinical analysis of the basic molecular mechanism involved in gefitinib-mediated anticancer effects in head and neck cancer is not available, e.g. in Shintani et al (20) gefitinib efficacy was investigated in only two HNSCC cell lines.
In this study, for the first time, the validation of gefitinib efficacy against head and neck cancer was performed in a broad panel of 12 newly established HNSCC cell lines and an extensive biological characterisation comprising cancer progression (including p53, Fhit, cell cycle characteristics and HPV infection) and EGFR-related markers (TK receptors, EGFR signal transduction pathway and ABCG2 expression), was also performed.
Inactivating mutations of the p53 tumour suppressor gene are the most common genetic event identified for almost all human cancers, including HNSCC, and changes in p53 status have been linked to disease progression, decreased sensitivity to chemotherapeutic agents and poor prognosis (21) . The key role of p53 in modulating EGFR expression (22) (23) (24) and in controlling cell proliferation and apoptosis poses the question of whether p53 status influences the efficacy of EGFR inhibitors. Moreover, the identification of two p53 homologues, p63 and p73 (25) with high identity of their amino acid sequence (about 63% in the DNA-binding domain) suggested a redundant function in the regulation of gene expression for these three transcription factors. p73 can activate p53-regulated genes, suppress growth or induce apoptosis (26) . Furthermore, TAp63 and ΔNp63, two p63 isoforms, perform opposite functions, inducing cell-cycle arrest and cell proliferation respectively; the latter is frequently expressed in HNSCC (27) .
Another factor analysed was Fhit (fragile histidine triad) which is frequently altered in head and neck cancer progression (28) . It was recently demonstrated that the activation of EGFR family members induced Fhit phosphorylation by Src and the subsequent proteasome degradation of the phosphorylated Fhit protein (29) , suggesting a key role for Fhit in the balance of proliferation/ survival/apoptosis signals and as a hypothetical predictive biomarker for gefitinib efficacy.
Another biological factor that has to be considered in head and neck cancer treatment with gefitinib, is human papillomavirus (HPV) status; HPV infection has been closely linked to oral cancer, with 30-40% of oral cancer biopsy specimens containing viral DNA of the high-risk HPV types, such as HPV-16, -18 and -33 (30, 31) .
The in vitro model was also characterised for the molecular alterations and expression of TK receptors and their downstream effectors (32) . The main EGFR downstream effectors analysed were AKT and Erk1/2, involved in the survival and proliferation pathways respectively, and the tumour suppressor gene, PTEN, as its inactivation can induce resistance to TK inhibitors (33) (34) (35) . The drug efflux pump ABCG2 (BCRP/MXR/ABCP) was also analysed in relation to gefitinib effectiveness in other cancer models (36) (37) (38) (39) . Finally, all HNSCC cell lines were analysed for the presence of mutations in the region of the EGFR gene coding for the tyrosine kinase domain (exon 18 to exon 21) and in the ATPase domain (exon 27 and 28) (18).
Materials and methods
Reagents. Gefitinib was provided by AstraZeneca Pharmaceuticals (London, UK). Stock solutions were prepared at 20 mM in dimethyl sulfoxide (DMSO) and stored in aliquots at -20˚C. The monoclonal antibody anti-EGFR was provided by BD Transduction Laboratories (USA); anti-ß-actin antibody was purchased from Sigma (Milan, Italy); antiphosphotyrosine PY99, anti-Fhit, anti-PTEN, anti-VEGFR2, and anti-ß-tubulin antibodies were provided by Santa Cruz Biotechnology (USA); anti-AKT, anti-phospho-AKT, anti-ERK1/2 and anti-phospho-ERK1/2 were provided by Cell Signaling (USA); anti-ABCG2 (human) MAb (BXP-21) by Alexis Corporation; and p53 polyclonal antibody NCL-CM1 and p63 polyclonal antibody were from Novocastra. A mouse and a rabbit HRP (Amersham Pharmacia Biotech, Uppsala Sweden) were used as secondary antibodies.
Establishment of human HNSCC cell lines. The excised tumour masses from different tissues of the head and neck region consisted of larynx (one case, HNC-150), oral cavity (six cases, HNC-91, -97, -124, -160, -199, -212), tonsil (three cases, HNC-41, -206, -211), hypopharynx (one case, HNC-180) and paranasal sinus (one case, HNC-136). These were minced and plated on dishes for explantation culture in DMEM supplemented with 20% FBS, 50 ng/ml of EGF, 10 μg/ml of hydrocortisone, and 5 μg/ml of spermine. The tissue samples were obtained from cancer patients during oral surgery. Confluent primary cells were trypsinized and further cultured in DMEM supplemented with 10% FCS, 2 mM glutamine and 2 mM penicillin-streptomycin (Life Technologies), in a humidified incubator at 37˚C with an atmosphere containing 5% CO 2 .
Evaluation of cytotoxicity. Determination of the IC 50 was performed using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazoliumbromide (MTT) assay. On day 1, 12,000 cells/well in a volume of 200 μl were plated in 96-well plates. In each plate, one column contained cells not exposed to drugs (control), and 5 columns contained cells exposed to increasing concentrations of gefitinib (from 10 nM to 100 μM) for three days. Each drug concentration was repeated in at least 6 identical wells. Gefitinib was added on day 2, and results were expressed as dose-effect curves with a plot of the fraction of unaffected (surviving) cells versus drug concentration. The IC 50 was defined as the drug concentration yielding a fraction of affected (non-surviving) cells (0.5) compared with untreated controls. Each experiment was conducted in triplicate.
Cell cycle analysis. Cells were exposed to gefitinib, harvested, washed twice in ice-cold PBS (pH 7.4), fixed in 4.5 ml of 70% ethanol and stored at -20˚C for at least 24 h. After being washed once in ice-cold PBS, the pellet was resuspended in PBS containing 1 mg/ml RNase and 0.01% NP40, and the cellular DNA was stained with 50 μg/ml propidium iodide (Sigma). Cells were stored in ice for 60 min prior to analysis. Cell cycle determinations were performed using a FACScan flow cytometer (Becton Dickinson), and data were interpreted using the CellQuest software, provided by the manufacturer. The DNA-ploidia pattern was evaluated comparing the shift of the G0/G1 peak of each cell line with respect to that of peripheral lymphocytes.
Determination of apoptosis.
Exponentially growing cells were treated with gefitinib IC 50 concentrations for 1-3 days. Apoptosis was evaluated using the Annexin V-FITC detection kit (BD Transduction) and by propidium iodide (PI) following the manufacturer's protocol. Oligonucleotide probes specific for 24 different HPV types were covalently attached to a membrane in parallel lines using a miniblotter. The templates used for analysis were DNA extracts previously labeled with biotin, using PCR. The labeled PCR products were then loaded onto the membrane in slots perpendicular to the oligo lines in order to allow all samples to interact with the HPV probes. Hybridisation took place in the miniblotter and was visualised using a peroxidase-labeled streptavidine, which interacted with the biotin of the PCR products, followed by chemiluminescence detection.
Determination of human papillomavirus (HPV) infection.
Western blot analysis. Total proteins were extracted from the cell culture by homogenisation in a radioimmunoprecipitation assay (RIPA) buffer [0.5 M NaCl, 1% Triton X-100, 0.5% NP40, 1% deoxycolic acid, 3.5 mM sodium dodecyl sulfate (SDS)], with a 20% protease inhibitor cocktail (Sigma, MO), and measured by the Bradford method. Proteins were electrophoretically separated by Western blotting and signals were detected by chemiluminescence assay. Expression levels were evaluated by densitometric analysis using Quantity One software (Bio-Rad, Hercules, CA) and the ß-actin expression level was used to normalise the sample values.
Immunoprecipitation assay. Cells were lysed in RIPA-IP buffer (140 mM NaCl, 20 mM Tris/HCl, 10 mM EDTA pH 8.0, 10% glycerol, 1% NP40, 1 mM Na-deoxycolic acid, 1 mM PMSF), passed through a 22-gauge syringe and cleared by centrifugation at 10,000 x g at 4˚C for 10 min. Proteins were immunoprecipitated by incubating 0.1-0.3 mg of total cell lysate with 0.2 μg of anti-phosphotyrosine antibody or EGFR antibody for 1 h at 4˚C. A/G agarose protein (2-5 μl) (Santa Cruz Biotechnology) was incubated overnight at 4˚C. The cell suspension was centrifuged at 2,600 rpm and the pellet was washed three times with PBS and then re-suspended in 10 μl of Laemmli buffer. Each sample was separated onto 10% acrylamide gel and Western blot analysis was performed as described above.
Reverse-transcription PCR. Each cell line was collected, the RNA was extracted with the Absolutely RNA Miniprep Kit (Stratagene) and 5 μg of RNA was converted to cDNA using the First Strand cDNA Synthesis Kit (Fermentas MBI). The primers used for the PCR were as follows: ΔNp73, 5'-ACC ATG CTG TAC GTC GGT GAC CCC-3' (forward) and 5'-GCG ACA TGG TGT CGA AGG TGG AGC-3' (reverse); ΔNp63, 5'-TGC CCA GAC TCA ATT TAG TGA G-3' (forward) and 5'-AGA GAG AGC ATC GAA GGT GGA G-3' (reverse); TAp63, 5'-GAC CTG AGT GAC CCC ATG TG-3' (forward) and 5'-CGG GTG ATG GAG AGA GAG CA-3' (reverse). As a control, the following human GAPDH was used: 5'-AAG GTG GTG AAG CAG GCG T-3' and 5'-GAG GAG TGG GTG TCG CTG TT-3'. Annealing temperatures and the number of cycles were specific for each isoform: ΔNp63, 25 cycles at 64˚C; TAp63, 35 cycles at 58˚C; ΔNp73, 40 cycles at 62˚C; and TAp73, 35 cycles at 61˚C. The rest of the PCR amplification consisted of 94˚C for 30 sec, for 30 sec, and 72˚C for 30 sec followed by incubation at 72˚C for 7 min. The bands were visualised by ethidium bromide staining.
DNA sequencing analysis. Randomly primed cDNAs were reverse-transcribed from 5 μg of total RNA using First Strand cDNA Synthesis Kit in a 40-μl mixture. Two microlitres of the cDNA mixture was used to amplify the p53 transcript (exons 4-9). PCR products were cloned into PCR II using a TA™ Cloning Kit (Invitrogen, San Diego, CA) under the conditions recommended by the manufacturer. The nucleotide sequence of the cloned DNA was determined by a Taq Dideoxy Terminator Cyclic Sequencing Kit on an ABI 377 Automatic DNA Sequencer (PerkinElmer, Foster City, CA).
Mutational analysis of EGFR. Genomic DNA was extracted from each cell line, using QIAamp DNA Blood Midi Kit (Qiagen) following the manufacturer's instructions. DNA was quantified and mutational analysis was performed from EGFR exons 18 to 21 and in exons 27 and 28. EGFR coding exon was amplified by PCR using the primers described in Table I. PCR amplification was carried out in a total volume of 50 μl containing 150 ng of genomic DNA as template, 1X reaction buffer, 1.5-3 mM magnesium chloride, 200 mM dNTP, 20-50 pmol of each PCR primer and 0.25 U AmpliTaq Gold. After PCR amplifications, 5 μl of the reaction product was analysed via gel electrophoresis and ethidium bromide staining. DNA sequencing was performed on both strands of two independent PCR products by cycle sequencing on an ABI PRISM 310 automated cycle sequencer, using the Terminator Cycle Sequencing Kit v.1.1 according to the manufacturer's protocol (Applied Biosystems, Table I . Primer sequences used for EGFR coding exon amplification. 
. Whenever an alteration was identified, a new DNA aliquot from the same cell line was sequenced to confirm the result. The variants found in the sequence were characterised and compared to those in the online databases, EntrezSNP (http://www.ncbi.nlm.nih.gov) and Ensembl (www.ensembl.org).
Results
The in vitro validation of gefitinib effectiveness in head and neck cancer was performed in a broad panel of head and neck cancer cell lines. Firstly, we investigated the efficacy of gefitinib. We then analysed our in vitro model for several characteristics connected with cancer progression (including p53, Fhit, cell cycle characteristics and HPV infection), and the anti-tumour activity of EGFR inhibitors (TK receptors, EGFR signal transduction pathway, ABCG2 expression and the presence of mutations in the region of the EGFR gene coding for the tyrosine kinase and ATPase domains), with the aim of identifying predictive factors for this TK inhibitor activity.
Gefitinib effectiveness. A broad panel of 12 HNSCC cell lines was established from different tissues of the head and neck area and stabilised (Table II) . This panel could be considered representative of head and neck cancer in in vitro studies.
The capability of gefitinib to inhibit cell growth was determined by incubating each HNSCC cell line with various drug concentrations for 3 days, and the results are reported as IC 50 values in Table II . Out of all cell lines, HNC-211 cells were the most sensitive to the drug, with IC 50 of 64 nM, and the most resistant ones were HNC-150 and -199 (IC 50 of 25 and 33 μM, respectively). The other cell lines showed 10-to 300-fold greater resistance to the drug than HNC-211.
Then, the capability of gefitinib to induce apoptosis was investigated by treating all cell lines with gefitinib at IC 50 concentration for 1-3 days. A 10-20% increase in Annexin V-positive cells was evident in only five cell lines: HNC-211, -124, -136, -199 and -150; the only difference among them was that the first two underwent apoptosis early (1-2 days) and this phenomenon decreased during the third day, while the Table II . Gefitinib effectiveness in HNSCC cell lines.
-----------------------------------------------------------------------------------------------------Cell line Site of origin 3-day gefitinib treatment --------------------------------------------------------------------------IC 50 (μM)
G0/G1 Apoptosis p-EGFR p-AKT p-Erk1/2 ± SD increase % expression % expression % expression % ---------------------------------------------------------------------------------------------------- Figure 1 . EGFR pathway modulation by gefitinib. HNSCC cells were incubated with gefitinib at IC 50 concentration and the protein extracts were analysed by immunoprecipitation and/or Western blotting. In Western blot analysis, the amount of the different targets was determined using monoclonal-or polyclonal-specific antibodies and ß-actin was used to normalise the values. p-EGFR was clearly detectable only in HCN-212 and HCN-206. last three showed progressive increase in Annexin V-positive cells as a function of time exposure (data not shown). The high variability of IC 50 values suggested the need to investigate the gefitinib activity in each cell line. In particular, the ability of gefitinib to modulate cell cycle progression was determined. A three-day drug exposure induced a slight blockage of the cell cycle at G0/G1 phase, with a maximum effect in HNC-206 inducing an increase in the accumulation of G0/G1 phase cells of ~22% (Table II) .
----------------------------------------------------------------------------------------------------
The drug-dependent modulation of EGFR and its downstream effectors, Akt and Erk1/2, was also investigated. Each cell line was treated with gefitinib at each IC 50 concentration for three days and the modulation of total and phosphorylated forms of EGFR, Erk1/2 and Akt was analysed. Gefitinib did not modulate the expression of EGFR, Akt and Erk1/2 (data not shown). Only HNC-212 and -206 cells showed detectable levels of p-EGFR expression and a 3-day gefitinib treatment showed 80% of residual EGFR in the phosphorylated form (Fig. 1) . p-Akt was completely abolished by gefitinib in four cell lines, HNC-41,-124, -97 and -212, and variously reduced in the remainder, conversely p-Erk1/2 was reduced to a lesser extent with the exception of HCN-180 and -160, as reported in Fig. 1 and summarised in Table II. Cell line characterisation. With the aim of identifying cellular or molecular factors that are predictive of gefitinib efficacy in our panel of head and neck cell lines, each cell line was characterised for targets related to cancer progression and drug activity.
In detail, expression and cell cycle distribution of Fhit and p53 family, were determined. As summarised in Table III , Fhit, the tumour suppressor that is frequently altered in head and neck cancer, was expressed only in two cell lines and a sequence analysis of exons 4-9 of the p53 gene provided evidence that 8 cell lines had mutated p53 and only four cell lines, either wild-type and mutated (HNC-124, -136, -211, -212), exhibited detectable levels of p53. Other p53 homologues analysed in our in vitro panel were p63 (TAp63, ΔNp63) and p73 (TAp73, ΔNp73). A preliminary RT-PCR analysis of ΔNp73 showed that it was detectable only in HNC-150 and -211, while a following nested PCR evidenced its presence in 75% of all the cell lines ( Fig. 2A) . TAp73 was detectable only in HNC-41 and HNC-136 by both RT-PCR and nested PCR (Fig. 2B) . Concerning p63 isoforms, ΔNp63 seemed to be overexpressed in eight cell lines by RT-PCR analysis, while nested PCR showed two more cell lines that were positive for this isoform expression (Fig. 2C) . The high expression level of ΔNp63 in HNSCC cell lines was confirmed by Western blot analysis and the results are shown in Fig. 2E . The expression levels of TAp63 were also analysed by RT-PCR and nested PCR, and it seemed to be present in all cell lines (Fig. 2D) . Cell cycle analysis showed that all cell lines had an atypical distribution in the G0/G1, S and G2/M phases and, with respect to lymphocytes, they were all aneuploid with a DNA index ranging between 1.13 and 1.75 (data not shown). Moreover, HNSCC cell lines analysed for the presence of HPV DNA (types 4, 5, 8, 9, 12, 14, 15, 17, 19-24, 26, 36-38 , 47-50, 60 and 65) showed that it was absent (data not shown). Our in vitro model was then analysed for several characteristics related to the mechanism of action of TK inhibitors, such as the expression levels of EGFR, p-EGFR, ErbB2, VEGFR-2, Erk1/2, p-Erk1/2, PTEN, Akt, and p-Akt. Higher levels of EGFR were observed in HNC-211, -199, and -206 cells whereas it was undetectable in HNC-91 and -136. Conversely, only HNC-206 and -212 showed detectable levels of p-EGFR (Fig. 3) . The other two TK receptors, ErbB2 and VEGFR-2, and the two signal transduction pathway effectors, Akt and Erk1/2, were ubiquitously expressed in all cell lines (Fig. 3) . Conversely, p-Akt and p-Erk1/2 Table III . Characterisation of HNSCC cell lines. (Fig. 3) . The tumour suppressor PTEN, was expressed ubiquitously in all cell lines (Fig. 4) . Recent evidence of a relationship between gefitinib and ABCG2 prompted us to characterise this drug efflux pump in our in vitro model; it was expressed in all cell lines with a higher expression in HNC-180, -199 and -136 (Fig. 4) . The results of the various cellular targets analysed are summarised in Table IV. Finally, mutational analysis, performed in the region of the EGFR gene coding for the tyrosine kinase domain and in the ATPase domain, showed that all cell lines were wildtype. However, this characterisation, utilising primers 
Discussion
The validity of our in vitro model for a complete analysis of gefitinib activity in HNSCC is supported by the evaluation of gefitinib efficacy in this panel, characterised by significant cell line-specific drug variability, i.e. HNC-211, was highly sensitive (IC 50 in nanomolar range) while HNC-150 showed the highest resistance (IC 50 =33 μM). Moreover, gefitinib was able to induce apoptosis after 3 days of exposure mainly in the most resistant cell lines. This was probably due to the high drug concentration responsive to a non-specificity of action. Notably, this TK inhibitor also induced apoptosis in two sensitive cell lines, suggesting that its ability to initiate the apoptotic process could be cell line-specific. This idea is supported by the evidence that in the resistant cells, apoptosis increased in a time-dependent manner leading to the hypothesis that the mechanism of drug saturation could be involved. Analysis of the modulation of EGFR signal transduction pathways by gefitinib showed that this drug, after three days of exposure, did not seem to inhibit EGFR phosphorylation. However, based on our previous evidence (40), we hypothesised that gefitinib inhibited EGFR activation early on, while after a prolonged exposure (3 days), the phosphorylated form of the receptor recovered its baseline level. Analysis of the ability of gefitinib to reduce the activation of the two main signal transduction pathways, PI3K/Akt/mTor and Ras/MAPK, was evidenced by a selective action on the first of these targets. Furthermore, PTEN was similarly expressed in all cell lines, in agreement with a low percentage of the inactivated form of this tumour suppressor reported in head and neck cancer (33, 41) , and the ubiquitous expression of ABCG2 did not allow the hypothesis of any correlation of this drug efflux pump with gefitinib sensitivity.
The cell variability for drug sensitivity suggested that we characterise our in vitro panel of HNSCC cell lines searching for predictive factors for gefitinib efficacy. We considered all biological characteristics involved in head and neck Table IV . Characterisation of HNSCC cell lines. . Moreover, only two cell lines, with medium sensitivity to gefitinib, were positive for Fhit expression suggesting that this factor is not directly correlated with the activity of this drug. The analysis of p53 family expression showed a variable distribution of cell lines with mutated p53 and/or the presence of the various isoforms of p63 and p73. No dependency on the drug activity was shown by the status of the p53 family. All cell lines were aneuploid with no difference between the most and the least sensitive lines. The lack of a dependency of gefitinib efficacy on the above described factors involved in head and neck cancer progression, prompted us to investigate the existence of a correlation between the activity of this drug and the expression level of cellular targets, such as TK receptors, downstream effectors, PTEN, and ABCG2, a drug efflux pump recently linked with gefitinib response (36) (37) (38) (39) . As reported in Table IV , the different distribution of the total and active forms of these targets did not allow the identification of any predictive factors, confirming that, as in other tumour types, gefitinib effectiveness in head and neck tumours, is not directly correlated with its target, EGFR. Finally, based on evidence that in lung cancer, certain mutations in the region of the EGFR gene coding for the ATPase and tyrosine kinase domains are related to drug sensitivity, we analysed our 12 cell lines for EGFR mutation status, confirming the data of Puhringer-Oppermann et al which suggested that these mutations are not relevant in determining gefitinib response in oral cancer (42) .
Although our cell characterisation did not identify any valid predictive factor for gefitinib effectiveness, the comparison between p53 family and EGFR expression suggested, for the first time, a correlation between the ΔNp63 isoform and EGFR expression level.
Transcription factors of the p53 family are mainly considered to be tumour suppressors, even though recent evidence demonstrated opposite functions for the p63 isoforms, ΔNp63 and TAp63, promoting cell proliferation and mimicking tumour suppressor p53 respectively (27) . Moreover, p53 family transcription factors are involved in the regulation of EGFR expression (23, 24) . In our study, two of the HNSCC cell lines did not express either ΔNp63 or EGFR, while the remainder co-expressed both proteins, suggesting a direct correlation between EGFR and ΔNp63 expression in the development of head and neck squamous cell carcinomas.
In conclusion, our study, performed in a broad panel of HNSCC cell lines, strongly confirmed the validity of gefitinib utilisation in head and neck cancer, however, it also demonstrated an urgent need to identify some valid predictive factors for the utilisation of tyrosine kinase inhibitors.
